Search

Your search keyword '"Arai, Katsuhiro"' showing total 297 results
Start Over Author "Arai, Katsuhiro" Language english
297 results on '"Arai, Katsuhiro"'

1. A nationwide survey of non-IgE-mediated gastrointestinal food allergies in neonates and infants

Author

Suzuki, Hiroko, Morisaki, Naho, Nagashima, Saori, Matsunaga, Tamotsu, Matsushita, Shoko, Iino, Akira, Tanaka, Yuichiro, Nishimori, Hisashi, Munakata, Shun, Kemmochi, Manabu, Murakami, Yoshitaka, Sato, Miori, Toyokuni, Kenji, Yamamoto-Hanada, Kiwako, Morita, Hideaki, Fukuie, Tatsuki, Yamada, Yoshiyuki, Ohtsuka, Yoshikazu, Arai, Katsuhiro, Ohya, Yukihiro, Saito, Hirohisa, Matsumoto, Kenji, and Nomura, Ichiro

Published
2024
Full Text
View/download PDF

2. Evaluation of safety and efficacy of autologous oral mucosa-derived epithelial cell sheet transplantation for prevention of anastomotic restenosis in congenital esophageal atresia and congenital esophageal stenosis

Author

Fujino, Akihiro, Fuchimoto, Yasushi, Mori, Teizaburo, Kano, Motohiro, Yamada, Yohei, Ohno, Michinobu, Baba, Yoshiyuki, Isogawa, Nobutaka, Arai, Katsuhiro, Yoshioka, Takako, Abe, Makoto, Kanai, Nobuo, Takagi, Ryo, Maeda, Masanori, and Umezawa, Akihiro

Published
2023
Full Text
View/download PDF

3. Clinical outcome of ulcerative colitis with severe onset in children: a multicenter prospective cohort study

Author

Nambu, Ryusuke, Arai, Katsuhiro, Kudo, Takahiro, Murakoshi, Takatsugu, Kunisaki, Reiko, Mizuochi, Tatsuki, Kato, Sawako, Kumagai, Hideki, Inoue, Mikihiro, Ishige, Takashi, Saito, Takeshi, Noguchi, Atsuko, Yodoshi, Toshifumi, Hagiwara, Shin-Ichiro, Iwata, Naomi, Nishimata, Shigeo, Kakuta, Fumihiko, Tajiri, Hitoshi, Hiejima, Eitaro, Toita, Nariaki, Mochizuki, Takahiro, Shimizu, Hirotaka, Iwama, Itaru, Hirano, Yuri, and Shimizu, Toshiaki

Published
2023
Full Text
View/download PDF

4. Human germline gain-of-function in STAT6: from severe allergic disease to lymphoma and beyond

Author

Sharma, Mehul, Suratannon, Narissara, Leung, Daniel, Baris, Safa, Takeuchi, Ichiro, Samra, Simran, Yanagi, Kumiko, Rosa Duque, Jaime S., Benamar, Mehdi, Del Bel, Kate L., Momenilandi, Mana, Béziat, Vivien, Casanova, Jean-Laurent, van Hagen, P. Martin, Arai, Katsuhiro, Nomura, Ichiro, Kaname, Tadashi, Chatchatee, Pantipa, Morita, Hideaki, Chatila, Talal A, Lau, Yu Lung, and Turvey, Stuart E

Published
2024
Full Text
View/download PDF

5. Expert consensus on vaccination in patients with inflammatory bowel disease in Japan

Author

Ishige, Takashi, Shimizu, Toshiaki, Watanabe, Kenji, Arai, Katsuhiro, Kamei, Koichi, Kudo, Takahiro, Kunisaki, Reiko, Tokuhara, Daisuke, Naganuma, Makoto, Mizuochi, Tatsuki, Murashima, Atsuko, Inoki, Yuta, Iwata, Naomi, Iwama, Itaru, Koinuma, Sachi, Shimizu, Hirotaka, Jimbo, Keisuke, Takaki, Yugo, Takahashi, Shohei, Cho, Yuki, Nambu, Ryusuke, Nishida, Daisuke, Hagiwara, Shin-ichiro, Hikita, Norikatsu, Fujikawa, Hiroki, Hosoi, Kenji, Hosomi, Shuhei, Mikami, Yohei, Miyoshi, Jun, Yagi, Ryusuke, Yokoyama, Yoko, and Hisamatsu, Tadakazu

Published
2023
Full Text
View/download PDF

7. Final Analysis of COVID-19 Patients With Inflammatory Bowel Disease in Japan (J-COSMOS): A Multicenter Registry Cohort Study

Author

Sasaki, Makoto, Iizuka, Masahiro, Fujiya, Mikihiro, Matsumoto, Takayuki, Kinjo, Fukunori, Nakamura, Shiro, Kamata, Noriko, Iijima, Hideki, Etani, Yuri, Ueno, Fumiaki, Hiraoka, Sakiko, Kondo, Takeo, Kagaya, Takashi, Naganuma, Makoto, Kobayashi, Kiyonori, Kobayashi, Taku, Yamamoto, Shuji, Naito, Yuji, Hisamatsu, Tadakazu, Furuta, Yoki, Mitsuyama, Keichi, Hashimoto, Yu, Arai, Katsuhiro, Kato, Shingo, Iwama, Itaru, Esaki, Motohiro, Tanaka, Hiroki, Nakase, Hiroshi, Motoya, Satoshi, Maemoto, Atsuo, Ashida, Toshifumi, Nishimata, Nobuaki, Aono, Shigeaki, Andoh, Akira, Yamamoto, Hironori, Ishihara, Shunji, Shimizu, Toshiaki, Yasuharu, Maeda, Kinoshita, Kenji, Fukuda, Katuyuki, Kato, Jun, Takeuchi, Ken, Nagahori, Masakazu, Fukuzawa, Masakatsu, Saruta, Masayuki, Suzuki, Takayoshi, Itabashi, Michio, Shinozaki, Masaru, Ishihara, Soichiro, Yoshimura, Naoki, Matsuoka, Katsuyoshi, Kakuta, Yoichi, Takahashi, Kenichi, Tominaga, Keiichi, Sakemi, Ryosuke, Nanjo, Sohachi, Yoshikawa, Shusaku, Ozeki, Keiji, Fuchigami, Ayako, Katsurada, Takehiko, Watanabe, Kenji, Sakuraba, Hirotake, Hirai, Fumihito, Hisabe, Takashi, Iwase, Shigeru, Ohmiya, Naoki, Hokari, Ryota, Nakai, Katsuhiko, Ueda, Takeshi, Abukawa, Daiki, Yamamoto, Shojiro, Koganei, Kazutaka, Kunisaki, Reiko, Hokama, Akira, Hayashi, Yuki, Yokoyama, Yoshihiro, and Matsuura, Minoru

Published
2023
Full Text
View/download PDF

10. A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation

Author

Kishi, Masahiro, Hirai, Fumihito, Takatsu, Noritaka, Hisabe, Takashi, Takada, Yasumichi, Beppu, Tsuyoshi, Takeuchi, Ken, Naganuma, Makoto, Ohtsuka, Kazuo, Watanabe, Kenji, Matsumoto, Takayuki, Esaki, Motohiro, Koganei, Kazutaka, Sugita, Akira, Hata, Keisuke, Futami, Kitarou, Ajioka, Yoichi, Tanabe, Hiroshi, Iwashita, Akinori, Shimizu, Hirotaka, Arai, Katsuhiro, Suzuki, Yasuo, and Hisamatsu, Tadakazu

Published
2022
Full Text
View/download PDF

12. Correction to: Expert consensus on vaccination in patients with inflammatory bowel disease in Japan

Author

Ishige, Takashi, Shimizu, Toshiaki, Watanabe, Kenji, Arai, Katsuhiro, Kamei, Koichi, Kudo, Takahiro, Kunisaki, Reiko, Tokuhara, Daisuke, Naganuma, Makoto, Mizuochi, Tatsuki, Murashima, Atsuko, Inoki, Yuta, Iwata, Naomi, Iwama, Itaru, Koinuma, Sachi, Shimizu, Hirotaka, Jimbo, Keisuke, Takaki, Yugo, Takahashi, Shohei, Cho, Yuki, Nambu, Ryusuke, Nishida, Daisuke, Hagiwara, Shin-ichiro, Hikita, Norikatsu, Fujikawa, Hiroki, Hosoi, Kenji, Hosomi, Shuhei, Mikami, Yohei, Miyoshi, Jun, Yagi, Ryusuke, Yokoyama, Yoko, and Hisamatsu, Tadakazu

Published
2023
Full Text
View/download PDF

14. Evaluation of Deficient Nutrients in Infants and Toddlers Mainly Taking Amino Acid-Based Elemental Formulas: An Exploratory Study.

Author

Takeuchi, Ichiro, Funayama, Rie, Shoji, Hiromichi, Nambu, Ryusuke, Jimbo, Keisuke, Hara, Tomoko, Shimizu, Hirotaka, Nomura, Ichiro, Iwama, Itaru, Kudo, Takahiro, Shimizu, Toshiaki, and Arai, Katsuhiro

Subjects
ASPARAGINE, RISK assessment, ESSENTIAL fatty acids, RESEARCH funding, MALNUTRITION, SELENIUM, FISHER exact test, NUTRITIONAL requirements, DESCRIPTIVE statistics, PHENYLALANINE, INFLAMMATORY bowel diseases, ENTERAL feeding, ELEMENTAL diet, EOSINOPHILIA, AMINO acids, NUTRITIONAL status, RESEARCH, VITAMINS, TYROSINE, VITAMIN C deficiency, SULFUR acids, GASTROINTESTINAL diseases, DISEASE risk factors, CHILDREN
Abstract

Introduction: This study evaluated nutrient deficiencies in infants and toddlers with inflammatory bowel disease (IBD) and eosinophilic gastrointestinal disorders (EGIDs), whose primary nutritional source is elemental formulas (EFs). Methods: The nutrient status of children with IBD and EGID aged 6 months to 6 years was evaluated. Results: Twenty-one children fed with EFs (EF group) and 25 controls (CL group) were enrolled. The selenium level in the EF group was lower than that in the CL group (2.2 μg/dL vs. 9.3 μg/dL; p < 0.01). Although fat-soluble vitamins were deficient in some EF group participants, no significant differences were observed in their concentration and insufficiency proportion. However, ascorbic acid deficiency was more frequent in the EF group, with significantly lower levels (8.6 μg/mL vs. 12.0 μg/mL; p < 0.01). The triene:tetraene ratio was significantly higher in the EF group (0.046 vs. 0.010; p < 0.01). Asparagine and taurine levels were significantly lower in the EF group (asparagine: p < 0.01; taurine: p < 0.01) and tyrosine and phenylalanine levels were higher in the EF group, resulting in a lower Fisher's ratio (p < 0.01). Conclusion: Long-term feeding with EFs can cause deficiencies in essential fatty acids, selenium, and ascorbic acid and also carries a risk of amino acid imbalance in infants and toddlers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Hematopoietic Cell Transplantation Rescues Inflammatory Bowel Disease and Dysbiosis of Gut Microbiota in XIAP Deficiency

Author

Ono, Shintaro, Takeshita, Kozue, Kiridoshi, Yuko, Kato, Motohiro, Kamiya, Takahiro, Hoshino, Akihiro, Yanagimachi, Masakatsu, Arai, Katsuhiro, Takeuchi, Ichiro, Toita, Nariaki, Imamura, Toshihiko, Sasahara, Yoji, Sugita, Junichi, Hamamoto, Kazuko, Takeuchi, Masanobu, Saito, Shoji, Onuma, Masaei, Tsujimoto, Hiroshi, Yasui, Masahiro, Taga, Takashi, Arakawa, Yuki, Mitani, Yuichi, Yamamoto, Nobuyuki, Imai, Kohsuke, Suda, Wataru, Hattori, Masahira, Ohara, Osamu, Morio, Tomohiro, Honda, Kenya, and Kanegane, Hirokazu

Published
2021
Full Text
View/download PDF

22. Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet’s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants

Author

Watanabe, Kenji, Tanida, Satoshi, Inoue, Nagamu, Kunisaki, Reiko, Kobayashi, Kiyonori, Nagahori, Masakazu, Arai, Katsuhiro, Uchino, Motoi, Koganei, Kazutaka, Kobayashi, Taku, Takeno, Mitsuhiro, Ueno, Fumiaki, Matsumoto, Takayuki, Mizuki, Nobuhisa, Suzuki, Yasuo, and Hisamatsu, Tadakazu

Published
2020
Full Text
View/download PDF

23. Antibodies to Crohn’s disease peptide 353 as a diagnostic marker for pediatric Crohn’s disease: a prospective multicenter study in Japan

Author

Mizuochi, Tatsuki, Arai, Katsuhiro, Kudo, Takahiro, Nambu, Ryusuke, Tajiri, Hitoshi, Aomatsu, Tomoki, Abe, Naoki, Kakiuchi, Toshihiko, Hashimoto, Kunio, Sogo, Tsuyoshi, Takahashi, Michiko, Etani, Yuri, Takaki, Yugo, Konishi, Ken-ichiro, Ishihara, Jun, Obara, Hitoshi, Kakuma, Tatsuyuki, Kurei, Shunsuke, Yamashita, Yushiro, and Mitsuyama, Keiichi

Published
2020
Full Text
View/download PDF

25. Prognosis of pediatric ulcerative colitis after infliximab failure: A multicenter registry‐based cohort study.

Author

Nambu, Ryusuke, Kudo, Takahiro, Tachibana, Nao, Shimizu, Hirotaka, Mizuochi, Tatsuki, Kato, Sawako, Inoue, Mikihiro, Kumagai, Hideki, Ishige, Takashi, Kunisaki, Reiko, Noguchi, Atsuko, Yodoshi, Toshifumi, Hagiwara, Shin‐Ichiro, Nishimata, Shigeo, Kakuta, Fumihiko, Saito, Takeshi, Iwama, Itaru, Hirano, Yuri, Shimizu, Toshiaki, and Arai, Katsuhiro

Subjects
ULCERATIVE colitis, FAILURE (Psychology), INFLAMMATORY bowel diseases, COHORT analysis, CHILD patients
Abstract

Background and Aim: Even with increasing numbers of biologic agents available for management of ulcerative colitis (UC), infliximab (IFX) retains an important place in treatment of pediatric patients with this disease. As few reports have addressed outcomes in pediatric UC patients who had to discontinue IFX, we examined clinical course and prognosis after IFX failure in pediatric UC. Methods: A prospective cohort study of pertinent cases enrolled in the Japanese Pediatric Inflammatory Bowel Disease Registry between 2012 and 2020 was conducted to determine outcomes for pediatric UC patients who received IFX but required its discontinuation during follow‐up (IFX failure). Results: Of the 301 pediatric UC patients in the registry, 75 were treated with IFX; in 36 of these, IFX was discontinued during follow‐up. Severity of UC at onset and absence of concomitant immunomodulator therapy were significant risk factors for IFX failure (P = 0.005 and P = 0.02, respectively). The cumulative colectomy rate after IFX failure was 41.3% at 1 year and 47.5% at 2 years. Colectomy was significantly more frequent when IFX was discontinued before June 1, 2018, than when IFX was discontinued later (P = 0.013). This difference likely involves availability of additional biologic agents for treatment of UC beginning in mid‐2018 (P = 0.005). Conclusion: In pediatric UC patients, approximately 50% underwent colectomy during a 2‐year interval following IFX failure. Prognosis after IFX failure appeared to improve with availability of new biologic agents and small‐molecule drugs in mid‐2018. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Anticoagulation against portal vein thrombosis reduces mortality and liver cirrhosis‐related complications: A propensity score‐matched study.

Author

Sato, Ayako, Watanabe, Sho, Iseki, Mari, Yamada, Yurina, Kobayashi, Ryohei, Furuya, Makoto, Arai, Katsuhiro, Ohshina, Eri, Tashiro, Yoshihiro, Nozaka, Takahito, Matsuoka, Mana, Yauchi, Masato, Kobayashi, Katsumasa, Matsumoto, Taichi, Furumoto, Yohei, Asano, Toru, and Azuma, Seishin

Subjects
PORTAL vein, ANTICOAGULANTS, THROMBOSIS, PROPENSITY score matching, LIVER
Abstract

Aim: Portal vein thrombosis (PVT) is one of the common complications of liver cirrhosis. Although anticoagulation contributes to thrombus resolution and is considered the first‐choice treatment, its impact on patients' prognosis is still controversial. This study aimed to clarify the benefit of anticoagulation on mortality, liver function, and the incidence of liver cirrhosis‐related complications in cirrhotic PVT patients. Methods: We conducted a multicenter retrospective review in which we included 78 eligible patients with PVT out of 439. After propensity score matching, 21 cirrhotic PVT patients were included in each one of the untreated control and anticoagulation groups. Results: Overall survival was significantly improved in the anticoagulation group compared with the control group (p = 0.041), along with PVT size reduction (53.3% vs. 108.2%, p = 0.009). At the time of CT follow‐up, the anticoagulation group showed a lower ALBI score (p = 0.037) and its prevalence of massive ascites was significantly lower (p = 0.043) compared with the control group. The incidence of overt encephalopathy was also lower in the anticoagulation group (p = 0.041). The cumulative incidence of bleeding events did not differ significantly between the two groups. Conclusions: Anticoagulation improves the survival of patients with cirrhotic PVT. Preserved liver function and reduced risks of cirrhosis‐related complications under the treatment may have contributed to a better prognosis. Given its efficacy and safety, anticoagulation is worth initiating in patients with PVT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Haploinsufficiency of A20 caused by a novel nonsense variant or entire deletion of TNFAIP3 is clinically distinct from Behçet’s disease

Author

Tsuchida, Naomi, Kirino, Yohei, Soejima, Yutaro, Onodera, Masafumi, Arai, Katsuhiro, Tamura, Eiichiro, Ishikawa, Takashi, Kawai, Toshinao, Uchiyama, Toru, Nomura, Shigeru, Kobayashi, Daisuke, Taguri, Masataka, Mitsuhashi, Satomi, Mizuguchi, Takeshi, Takata, Atsushi, Miyake, Noriko, Nakajima, Hideaki, Miyatake, Satoko, and Matsumoto, Naomichi

Published
2019
Full Text
View/download PDF

36. Serum leucine‐rich alpha‐2 glycoprotein and calprotectin in children with inflammatory bowel disease: A multicenter study in Japan.

Author

Yasuda, Ryosuke, Arai, Katsuhiro, Kudo, Takahiro, Nambu, Ryusuke, Aomatsu, Tomoki, Abe, Naoki, Kakiuchi, Toshihiko, Hashimoto, Kunio, Sogo, Tsuyoshi, Takahashi, Michiko, Etani, Yuri, Kato, Ken, Yamashita, Yushiro, Mitsuyama, Keiichi, and Mizuochi, Tatsuki

Subjects
*INFLAMMATORY bowel diseases, *CALPROTECTIN, *CROHN'S disease, *RECEIVER operating characteristic curves, *IRRITABLE colon
Abstract

Background and Aim: Serum leucine‐rich alpha‐2 glycoprotein (LRG) and calprotectin have been studied as disease activity markers in adults with inflammatory bowel disease (IBD). We evaluated them in pediatric IBD patients. Methods: Subjects under 17 years old undergoing care at 11 Japanese pediatric centers were retrospectively assigned to 3 groups representing Crohn's disease (CD), ulcerative colitis (UC), and normal controls (NC) with irritable bowel syndrome or no illness. Serum LRG and calprotectin were measured using commercial enzyme‐linked immunosorbent assay kits. Results: We enrolled 173 subjects, including 74 with CD, 77 with UC, and 22 NC. Serum LRG concentrations in active CD (median, 200 μg/mL) were significantly greater than in remission (81 μg/mL; P < 0.001) or NC (69 μg/mL; P < 0.001). Serum calprotectin concentrations in active CD (2941 ng/mL) also were significantly greater than in remission (962 ng/mL; P < 0.05) or NC (872 ng/mL; P < 0.05). Serum LRG concentrations in active UC (134 μg/mL) were significantly greater than in remission (65 μg/mL; P < 0.01) but not significantly greater than in NC (69 μg/mL); serum calprotectin concentrations in active UC (1058 ng/mL) were not significantly different from those in remission (671 ng/mL) or NC (872 ng/mL). In receiver operating characteristic analyses of LRG, calprotectin, C‐reactive protein, and erythrocyte sedimentation rate for ability to distinguish active IBD from remission, CD and UC showed areas under receiver operating characteristic curves for LRG (0.77 and 0.70, respectively), exceeding those for calprotectin, C‐reactive protein, or erythrocyte sedimentation rate. Conclusions: In pediatric IBD, serum LRG may better reflect disease activity than serum calprotectin, particularly in CD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan.

Author

Yokoyama, Koji, Yamamoto, Yoko, Nambu, Ryusuke, Hagiwara, Shin‐Ichiro, Abukawa, Daiki, Mizuochi, Tatsuki, Kudo, Takahiro, Sado, Tomomitsu, Iwata, Naomi, Ishige, Takashi, Iwama, Itaru, Kumagai, Hideki, Arai, Katsuhiro, and Shimizu, Toshiaki

Subjects
ULCERATIVE colitis, CHILD patients, BLOOD sedimentation, VEDOLIZUMAB, SERUM albumin
Abstract

Background: Vedolizumab (VDZ) is a humanized monoclonal antibody that binds to α4β7 integrin expressed in T‐lymphocytes and is gut selective. Few studies have evaluated the safety and efficacy of VDZ in pediatric ulcerative colitis (UC) patients, especially from Asia. Methods: A longitudinal multicenter retrospective study was conducted at 10 Japanese tertiary medical institutions. Patients aged ≤18 years old who received VDZ for UC between January 2019 and July 2021 were enrolled. Information on the clinical characteristics, prior/concomitant treatment, and safety during the observation period was collected. Results: The data obtained from 48 patients (males, n = 30; females, n = 18) were analyzed. The median age at VDZ induction was 14 (range 4–18) years old. VDZ was indicated in 73% of patients as switching from previous biologics due to primary failure, loss of response, and adverse events (AEs) and was the first biologic in 27%. Remission was achieved or maintained at weeks 14, 30, and 54 in 79.2%, 75.0%, and 65.8% of patients, respectively. There were no significant differences between the number of previous biologics exposures and VDZ effectiveness. The hematocrit, serum albumin concentrations, and erythrocyte sedimentation rate (ESR) at baseline differed significantly by VDZ effectiveness. Nine AEs, including infusion reaction, were noted in seven (14.3%) patients. There were no severe AEs related to VDZ administration. Conclusions: VDZ was safe and effective in children with UC. The hematocrit, albumin, and ESR at VDZ initiation might be predictors for VDZ effectiveness. VDZ may be an important option for pediatric patients and can be used as an alternative to immunomodulators. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group.

Author

Lee, Way Seah, Arai, Katsuhiro, Alex, George, Treepongkaruna, Suporn, Kim, Kyung Mo, Choong, Chee Liang, Mercado, Karen S. C., Darma, Andy, Srivastava, Anshu, Aw, Marion M., Huang, James, Ni, Yen Hsuan, Malik, Rohan, Tanpowpong, Pornthep, Tran, Hong Ngoc, and Ukarapol, Nuthapong

Subjects
*INFLAMMATORY bowel diseases, *PEDIATRIC gastroenterology, *HEPATOLOGY, *NUTRITION, *MEDICAL personnel
Abstract

Pediatric inflammatory bowel disease (PIBD) is rising rapidly in many industrialized and affluent areas in the Asia‐Pacific region. Current available guidelines, mainly from Europe and North America, may not be completely applicable to clinicians caring for children with PIBD in this region due to differences in disease characteristics and regional resources constraints. This position paper is an initiative from the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology and Nutrition (APPSPGHAN) with the aim of providing an up‐to‐date, evidence‐based approach to PIBD in the Asia‐Pacific region, taking into consideration the unique disease characteristics and financial resources available in this region. A group of pediatric gastroenterologists with special interest in PIBD performed an extensive literature search covering epidemiology, disease characteristics and natural history, management, and monitoring. Gastrointestinal infections, including tuberculosis, need to be excluded before diagnosing IBD. In some populations in Asia, the Nudix Hydrolase 15 (NUD15) gene is a better predictor of leukopenia induced by azathioprine than thiopurine‐S‐methyltransferase (TPMT). The main considerations in the use of biologics in the Asia‐Pacific region are high cost, ease of access, and potential infectious risk, especially tuberculosis. This position paper provides a useful guide to clinicians in the medical management of children with PIBD in the Asia‐Pacific region. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Management and monitoring of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group: Surgical management, disease monitoring, and special considerations

Author

Lee, Way Seah, Arai, Katsuhiro, Alex, George, Treepongkaruna, Suporn, Kim, Kyung Mo, Choong, Chee Liang, Mercado, Karen Calixto, Darma, Andy, Srivastava, Anshu, and Aw, Marion M.

Subjects
*INFLAMMATORY bowel diseases, *PEDIATRIC gastroenterology, *CROHN'S disease, *BONE health, *RESOURCE-limited settings
Abstract

Disease phenotype of pediatric inflammatory bowel disease (PIBD) in children from the Asia‐Pacific region differs from that of children from the West. Many parts of Asia are endemic for tuberculosis, making diagnosis and management of pediatric Crohn's disease a challenge. Current available guidelines, mainly from Europe and North America, may not be completely applicable to clinicians caring for children with PIBD in Asia due to differences in disease characteristics and regional resource constraints. This position paper is an initiative from the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology and Nutrition (APPSPGHAN) that aims to provide an up‐to‐date, evidence‐based approach to PIBD in the Asia‐Pacific region. A group of pediatric gastroenterologists with a special interest in PIBD performed an extensive literature search covering epidemiology, disease characteristics and natural history, management, and monitoring. Attention was paid to publications from the region with special consideration to a resource‐limited setting. This current position paper deals with surgical management, disease monitoring, immunization, bone health, and nutritional issues of PIBD in Asia. A special section on differentiating pediatric Crohn's disease from tuberculosis in children is included. This position paper provides a useful guide to clinicians in the surgical management, disease monitoring, and various health issues in children with IBD in Asia‐Pacific region. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Prospective Study of Allogeneic Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide and Antithymocyte Globulin from HLA-Mismatched Related Donors for Nonmalignant Diseases

Author

Osumi, Tomoo, Yoshimura, Satoshi, Sako, Mayumi, Uchiyama, Toru, Ishikawa, Takashi, Kawai, Toshinao, Inoue, Eisuke, Takimoto, Tetsuya, Takeuchi, Ichiro, Yamada, Masaki, Sakamoto, Kenichi, Yoshida, Kaoru, Kimura, Yui, Matsukawa, Yukihiro, Matsumoto, Kana, Imadome, Ken-Ichi, Arai, Katsuhiro, Deguchi, Takao, Imai, Kohsuke, Yuza, Yuki, Matsumoto, Kimikazu, Onodera, Masafumi, Kanegane, Hirokazu, Tomizawa, Daisuke, and Kato, Motohiro

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results